Literature DB >> 20671267

Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS.

Heather Vinet-Oliphant1, Xavier Alvarez, Elizabeth Buza, Juan T Borda, Mahesh Mohan, Pyone P Aye, Florin Tuluc, Steven D Douglas, Andrew A Lackner.   

Abstract

Recent studies suggest a link between neuropsychiatric disorders and HIV/SIV infection. Most evidence indicates that monocytes/macrophages are the primary cell type infected within the CNS and that they contribute to CNS inflammation and neurological disease. Substance P (SP), a pleotropic neuropeptide implicated in inflammation, depression, and immune modulation via interaction with its cognate receptor, the neurokinin 1 receptor (NK1-R), is produced by monocyte/macrophages. While the presence of NK1-R on neurons is well known, its role on cells of the immune system such as monocyte/macrophages is just beginning to emerge. Therefore, we have examined the expression of SP and NK1-R and their relationship to SIV/HIV encephalitis (SIVE/HIVE) lesions and SIV-infected cells. These studies demonstrated intense expression of SP and NK1-R in SIVE lesions, with macrophages being the principal cell expressing NK1-R. Interestingly, all of the SIV-infected macrophages expressed NK1-R. Additionally, we examined the functional role of SP as a proinflammatory mediator of monocyte activation and chemotaxis. These studies demonstrated that treatment of monocytes with SP elicited changes in cell-surface expression for CCR5 and NK1-R in a dose-dependent manner. Moreover, pretreatment with SP enhanced both SP- and CCL5-mediated chemotaxis. All of these findings suggest that SP and NK1-R are important in SIV infection of macrophages and the development of SIVE lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671267      PMCID: PMC2928962          DOI: 10.2353/ajpath.2010.091109

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS.

Authors:  Kenneth C Williams; William F Hickey
Journal:  Annu Rev Neurosci       Date:  2002-03-27       Impact factor: 12.449

Review 3.  Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism.

Authors:  Pasquale Annunziata
Journal:  J Neurol       Date:  2003-08       Impact factor: 4.849

4.  HIV enhances substance P expression in human immune cells.

Authors:  Wen-Zhe Ho; Jian-Ping Lai; Yuan Li; Steven D Douglas
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

5.  Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium.

Authors:  Pasquale Annunziata; Chiara Cioni; Riccardo Santonini; Eugenio Paccagnini
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

Review 6.  The role of substance P in inflammatory disease.

Authors:  Terence M O'Connor; Joseph O'Connell; Darren I O'Brien; Triona Goode; Charles P Bredin; Fergus Shanahan
Journal:  J Cell Physiol       Date:  2004-11       Impact factor: 6.384

7.  Endosomal endothelin-converting enzyme-1: a regulator of beta-arrestin-dependent ERK signaling.

Authors:  Graeme S Cottrell; Benjamin E Padilla; Silvia Amadesi; Daniel P Poole; Jane E Murphy; Markus Hardt; Dirk Roosterman; Martin Steinhoff; Nigel W Bunnett
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

Review 8.  HIV disease progression: depression, stress, and possible mechanisms.

Authors:  Jane Leserman
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

9.  A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes.

Authors:  Jian-Ping Lai; Wen-Zhe Ho; Ji-Hong Yang; Xu Wang; Li Song; Steven D Douglas
Journal:  J Neuroimmunol       Date:  2002-07       Impact factor: 3.478

10.  The third intracellular loop and carboxyl tail of neurokinin 1 and 3 receptors determine interactions with beta-arrestins.

Authors:  Fabien Schmidlin; Dirk Roosterman; Nigel W Bunnett
Journal:  Am J Physiol Cell Physiol       Date:  2003-10       Impact factor: 4.249

View more
  16 in total

1.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

2.  A single amino acid mutation in the envelope cytoplasmic tail restores the ability of an attenuated simian immunodeficiency virus mutant to deplete mucosal CD4+ T cells.

Authors:  Matthew W Breed; Andrea P O Jordan; Pyone P Aye; Chie Sugimoto; Xavier Alvarez; Marcelo J Kuroda; Bapi Pahar; Brandon F Keele; James A Hoxie; Andrew A Lackner
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 3.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

4.  Substance P-mediated chemokine production promotes monocyte migration.

Authors:  Sergei Spitsin; John Meshki; Angela Winters; Florin Tuluc; Tami D Benton; Steven D Douglas
Journal:  J Leukoc Biol       Date:  2016-10-21       Impact factor: 4.962

5.  Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression.

Authors:  Matthew W Breed; Andrea P O Jordan; Pyone P Aye; Cornelis F Lichtveld; Cecily C Midkiff; Faith R Schiro; Beth S Haggarty; Chie Sugimoto; Xavier Alvarez; Netanya G Sandler; Daniel C Douek; Marcelo J Kuroda; Bapi Pahar; Michael Piatak; Jeffrey D Lifson; Brandon F Keele; James A Hoxie; Andrew A Lackner
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  Expression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathology.

Authors:  Sergei Spitsin; Kathleen E Stevens; Steven D Douglas
Journal:  J Neurol Sci       Date:  2013-08-02       Impact factor: 3.181

7.  Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.

Authors:  Lynnae Schwartz; Sergei V Spitsin; John Meshki; Florin Tuluc; Steven D Douglas; John H Wolfe
Journal:  J Neurovirol       Date:  2013-06-14       Impact factor: 2.643

8.  Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.

Authors:  Sergei Spitsin; Florin Tuluc; John Meshki; Jian Ping Lai; Richard Tustin Iii; Steven D Douglas
Journal:  Neuroimmunomodulation       Date:  2013-07-05       Impact factor: 2.492

9.  Depression severity is associated with increased risk behaviors and decreased CD4 cell counts.

Authors:  Toshibumi Taniguchi; Enbal Shacham; Nur Fiona Onen; Jessica Rosenbaum Grubb; Edgar Turner Overton
Journal:  AIDS Care       Date:  2014-01-30

Review 10.  A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.

Authors:  Chenere P Ramsey; Malú G Tansey
Journal:  Exp Neurol       Date:  2013-05-28       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.